Ann: Paradigm Presentation to Emerging Leaders Conference, page-66

Thanks all - it was provisional approval from the TGA, not full approval.

And I think the reference to provisional approval coming after FDA Phase 3 was listed in the Coppo Report which I found surprising as Coppo has PAR as his number 1 stock choice for the year ahead of APT and A2M. However, it may have been in the research section and therefore done by another analyst.

In any event, it seems we will know shortly the plans for TGA provisional approval application which will be exciting, as if there can be revenue by next year I am sure we will all not be so worried about recent share price action...